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An extremely high dose of losartan affords superior renopro-
tection in the remnant model.
Background. Rats subjected to 5/6 renal ablation (NX) ex-
hibit large renal amounts of angiotensin II (Ang II) and of its
main receptor, AT-1R. At previously used doses, AT-1R block-
ers (ARB) offer only partial renal protection. A possible expla-
nation for this limited effect is that these doses are insufficient to
block most of the abnormally expressed AT-1R. We investigated
whether extremely high doses of the ARB, losartan (L), offer
better protection than conventional doses in the NX model.
Methods. Thirty days after NX, tail-cuff pressure (TCP), al-
buminuria (UalbV, mg/day), glomerulosclerosis index (GSI),
fractional interstitial area (%INT), and macrophage infiltra-
tion (MØ) were evaluated in a separate group (NXpre). The
remaining rats were then subdivided among 4 groups: NX+V,
receiving vehicle; NX+L50, treated with L, at the “conven-
tional” dose of 50 mg/kg/day; NX+L500, receiving L, 500
mg/kg/day; and NX+HH, receiving hydrochlorothiazide and
hydralazine to lower blood pressure to a similar extent as in
group L500.
Results. After a month of treatment, blood pressure and re-
nal vascular resistance were lowest in group L500. Glomeru-
lar pressure was lowered by a similar extent by L50 and L500,
while GFR was similar among groups. UalbV, TCP, and renal
injury were only partially reduced by L50 120 days after renal
ablation. By contrast, L500 arrested renal inflammation and
glomerular/interstitial injury at pretreatment levels, and pro-
moted regression of hypertension and UalbV, causing no appar-
ent untoward effects.
Conclusion. The renal protection afforded by ARB in NX is
dose dependent. Maximal protection may require doses several
fold higher than those currently employed.
Chronic nephropathies, which lead to glomerulosclero-
sis, renal fibrosis, and end-stage renal failure, can be initi-
ated by immune and nonimmune mechanisms. Whatever
their origin, the propagation and perpetuation of chronic
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nephropathies require the participation of inflammatory
events such as macrophage infiltration [1], fibroblast pro-
liferation [2], and excessive production of extracellular
matrix [3]. These processes require, in turn, the occur-
rence of a complex chain of cellular events that include
the proliferation of lymphocytes and macrophages [4],
the synthesis of cytokines and chemokynes [5], the re-
lease of growth factors [6], and the expression of adhesion
molecules [7].
Angiotensin II (Ang II) is deeply involved in the patho-
genesis of chronic nephropathies. The generalized vaso-
constriction and enhanced proximal sodium absorption
promoted by Ang II, primarily aimed at defending blood
pressure and the extracellular volume, can elevate sys-
temic and intraglomerular pressure, leading to mechan-
ical aggression to the walls of glomeruli and arterioles.
Recent evidence has shown that, besides this “hemo-
dynamic” effect, Ang II participates directly in the in-
flammatory response that follows initial mechanic or
immunologic insult. In renal and nonrenal tissue, Ang II
stimulates the expression of a host of inflammatory
mediators such as growth factors [8, 9], cytokines and
chemokines [10, 11], and adhesion molecules [12], as well
as the proliferation of lymphocytes [13]. In addition, in-
flammatory cells can produce Ang II [14], thus generat-
ing a positive feedback mechanism that could contribute
to the propagation and perpetuation of chronic inflam-
mation and to the development of irreversible injury
to the renal parenchyma. The production of “inflamma-
tory” Ang II must be influenced by local rather than sys-
temic hemodynamic factors, since the available models
of chronic renal disease, usually associated with sodium
retention, would tend to depress rather than stimulate
the renin-angiotensin system.
Evidence that Ang II originated in the renal tissue
participates in local inflammatory events and in the de-
velopment of progressive nephropathies has steadily ac-
cumulated in recent years. In the 5/6 renal ablation
model (NX), angiotensinogen mRNA can be shown
in the glomeruli [15], whereas Ang II itself appears
in tubules, mesangial cells, and interstitial cells in the
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weeks following nephrectomy [16, 17]. The intensity
of interstitial Ang II expression associates closely with
the severity of renal injury [17, 18]. Similar findings
were obtained in the chronic nitric oxide inhibition
model [19, 20]. More recent studies showed that, in
both models, AT-1 receptors are massively expressed in
inflamed interstitial areas [17, 19], consistent with the
hypothesis that Ang II exerts a pathogenic role in this
process.
Angiotensin-converting enzyme inhibitors (ACEI)
and AT-1 receptor blockers (ARB) have been intensely
utilized in the treatment of progressive nephropathies
[21–23]. Although the advent of these compounds rep-
resented a major therapeutic advance, they fail to com-
pletely arrest the progression of advanced disease, only
postponing the need for renal replacement therapy [21,
22]. In experimental nephropathies, this limitation be-
comes evident in studies in which therapy with these
compounds is started late in the course of the disease,
allowing substantial previous progression of renal injury
[17, 24, 25]
Doses of ACEI and ARB currently employed in clini-
cal practice and even in experimental protocols are based
essentially on the observation of the maximal effects of
these drugs on blood pressure. These hemodynamic ef-
fects depend basically on the availability of AT-1 recep-
tors on vascular smooth muscle cells. However, we have
recently shown that, in the 5/6 renal ablation model, AT-1
receptors are intensely expressed in inflamed areas of the
renal parenchyma [17]. This finding raised the possibility
that “conventional” doses of these drugs may be insuffi-
cient to completely neutralize the anomalous activation
of the renin-angiotensin system, thus helping to explain
their failure to achieve complete renal protection. Since
these drugs are very well tolerated, it is conceivable that,
at doses currently considered as “extremely high,” they
may confer much more efficient renal protection than
“conventional” doses. In accordance with this notion, the
protective effect of the ARB, irbesartan, was shown to be
dose dependent in a large trial of diabetic nephropathy
[26].
In the present study, we investigated whether the use of
an “extremely high” dose (one order of magnitude higher
than “conventional” doses) of the ARB, losartan potas-
sium (L), would be well tolerated and exert a superior
renoprotective effect in the NX model. Treatments were
initiated 30 days after renal ablation, thus mimicking what
usually occurs in the management of human progressive
nephropathies. We also verified whether a possible salu-
tary effect of high-dose L treatment would be associated
with amelioration of systemic hypertension, of glomeru-
lar hypertension, or of the associated inflammatory pro-
cess, or would instead involve a combined effect of these
mechanisms.
METHODS
One hundred thirty-seven adult male Munich-Wistar
rats, weighing initially between 230 and 260 g were uti-
lized in this study. Rats were obtained from a local facility
at the University of Sa˜o Paulo, and maintained at 23 ±
1◦C, with relative air humidity at 60 ± 5% and under
12-hour light/dark cycle. Five-sixth nephrectomy (NX)
was performed after ventral laparotomy under anesthe-
sia with sodium pentobarbital, 50 mg/kg IP, by removal
of the right kidney and ligation of 2 branches of the left
renal artery, resulting in the infarction of two thirds of
the left kidney. Sham-operated rats (S) underwent anes-
thesia and manipulation of the renal pedicles, without
removal of renal mass. After recovering from anesthesia,
the animals were returned to their original cages, which
were kept warmed during the following 24 hours. All an-
imals were given free access to tap water and standard
chow (0.5 Na, 22% protein). All experimental procedures
were approved by the local Research Ethics Committee
(CAPPesq, process no. 368/02), and developed in strict
conformity with our institutional guidelines and with in-
ternational standards for manipulation and care of labo-
ratory animals.
Experimental groups
Thirty days after renal ablation, tail-cuff pressure
(TCP) and the daily urinary albumin excretion (UalbV)
were determined in all rats. Rats failing to increase TCP
above 160 mm Hg or UalbV above 30 mg/day were not
included in the study. Twenty-two of the rats that ful-
filled these criteria were utilized as pretreatment control
subjects, and were followed no further (group NXpre).
The remaining 96 NX animals were subdivided into 4
additional experimental groups: NX+V (N = 26), re-
ceiving pure tap water; NX+L50 (N = 25), receiving
the ARB losartan potassium (L), 200 mg/L in the drink-
ing water, corresponding to an average daily intake of
50 mg/kg; NX+L500 (N = 22), receiving L, 2000 mg/L
in the drinking water, corresponding to an average daily
intake of 500 mg/kg/day. This was the maximal L dose not
resulting in growth stunting; NX+HH (N = 23), receiv-
ing hydralazine, 100 mg/L in the drinking water, corre-
sponding to an average daily intake of 24 mg/kg/day, and
hydrochlorothiazide, 25 mg/L in the drinking water, cor-
responding to an average daily intake of 6 mg/kg/day. This
last group was included to evaluate the degree of renal
protection that would be afforded by decreasing TCP to a
similar extent as in group NX+L500, without suppressing
the renin-angiotensin system. Nineteen sham-operated
rats (group S) received pure tap water only and served as
control subjects. To reproduce the situation usually en-
countered in clinical practice, all drug treatments were
started only 30 days after renal ablation, when chronic
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renal injury associated with this model is known to be un-
der progression [17]. The distribution of NX rats into the
experimental groups described above (except for NXpre)
was performed in such a fashion as to ensure that initial
values for both mean TCP and UalbV were similar among
groups.
Functional studies
Thirty days after treatments were started (60 days after
renal ablation), 8 rats from each of the groups described
above were anesthetized with inactin, 100 mg/kg, IP, and
prepared for whole kidney and glomerular hemodynamic
studies, in which mean arterial pressure (MAP), glomeru-
lar filtration rate (GFR), renal plasma flow (RPF), re-
nal vascular resistance (RVR), and glomerular hydraulic
pressure (PGC) were determined. The details of the ex-
perimental procedures and analytic techniques utilized
in these studies are given elsewhere [4].
At the end of each experiment, the kidneys were per-
fused with saline solution at the MAP and fixed in situ,
still at the MAP, with Duboscq-Brasil solution. The renal
tissue was then prepared for morphologic evaluation.
Long-term studies
Rats from groups S (N = 11), NX+V (N = 18),
NX+L50 (N = 17), NX+L500 (N = 14), and NX+HH
(N = 15) were followed during 120 days after ablation
(90 days of treatment), with monthly determination of
TCP and UalbV. Since initial and final values for TCP
and UalbV were obtained in the same animals, direct-
paired comparisons could be performed. At the end of
this period, all rats were anesthetized with sodium pen-
tobarbital, 50 mg/kg, IP, and blood samples were drawn
from the abdominal aorta for determination of plasma
sodium and potassium concentration. The kidneys were
then perfusion-fixed as described above. The same proce-
dure had been adopted for the 22 rats from group NXpre
(pretreatment reference), studied 30 days after renal ab-
lation.
Histologic techniques and histomorphometry
After fixation, the kidneys were weighed and 2 mid-
coronal sections were postfixed in buffered 4% formalde-
hyde. The renal tissue was then embedded in paraffin
using standard sequential techniques, and prepared for
assessment of glomerular, interstitial, and vascular injury,
as well as for immunohistochemical analysis, as described
previously [4].
Morphometric evaluations were always performed in
a blinded manner by a single observer in 4-lm thick sec-
tions. For each rat, the severity of glomerulosclerosis (GS)
was estimated, in sections stained with periodic acid–
Schiff (PAS), by attributing to each glomerulus a score
that reflected the fraction of the tuft area taken by the
sclerosing lesion, as described previously [4]. A GS index
(GSI) was calculated for each rat as the weighted aver-
age of the individual glomerular scores obtained in this
manner multiplied by 100. At least 120 glomeruli were
examined for each rat. The extent of interstitial expan-
sion was assessed by estimating, using a point-counting
technique [27], the percentage of the renal cortical area
occupied by interstitial tissue (%INT). This procedure
was carried in Masson-stained sections by examining 25
consecutive microscopic fields, at a final magnification of
100×, under a 176-point grid.
Immunohistochemistry
Immunohistochemical procedures were always car-
ried on 4-lm thick, paraffin-embedded renal sections,
mounted on glass slides coated with 2% gelatin. Sections
were initially deparaffinized and rehydrated using stan-
dard techniques, then exposed to microwave irradiation
in citrate buffer to enhance antigen retrieval, and prein-
cubated with 5% normal rabbit (for ED-1) or horse (for
AT-1 and Ang II) serum in Tris-buffered saline (TBS)
to prevent nonspecific binding. Incubation with the pri-
mary antibody was always carried out overnight at 4◦C in
a humidified chamber. Negative control experiments for
all antigens were performed by omitting incubation with
the primary antibody.
For macrophage detection, a monoclonal mouse an-
tirat ED-1 antibody (Serotec, Oxford, UK) was used.
After washing, sections were incubated with rabbit an-
timouse immunoglobulins (Dako, Glostrup, Denmark),
then with an alkaline phosphatase antialkaline phos-
phatase (APAAP; Dako) complex. Finally, sections were
developed with a fast-red dye solution, counterstained
with Mayer’s hemalaum, and covered with Kaiser’s
glycerin-gelatin (Merck, Darmstadt, Germany).
Ang II- and AT1R-positive cells were detected by an
indirect streptavidin-biotin alkaline phosphatase tech-
nique. For Ang II detection, a monoclonal rabbit anti-
human Ang II (Peninsula Lab., San Carlos, CA, USA)
was used, whereas AT1R was detected with a mono-
clonal rabbit antirat AT1R antibody (RDI, Flanders, NJ,
USA). Sections were preincubated with avidin and bi-
otin solutions to block nonspecific binding of these com-
pounds (Blocking Kit, Vector Labs, Burlingame, CA,
USA). After washing, the sections were incubated at
room temperature with rat-adsorbed biotinylated an-
timouse or antirabbit IgG (Vector Labs) for 45 min-
utes, then with a streptavidin-biotin-alkaline phosphatase
complex (Dako) for an additional 30 minutes. Sections
were finally incubated with a freshly prepared substrate
consisting of naphthol AS-MX-phosphate and developed
as described above.
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Table 1. Hemodynamic studies after 30 days of treatment (60 days after ablation)
BW LKW MAP GFR RPF RVR PGC
g mm Hg mL/min mm Hg/mL/min mm Hg
S 333 ± 9 1.5 ± 0.03 114 ± 2 1.4 ± 0.1 4.6 ± 0.4 14 ± 1 53 ± 1
(N = 8)
NXpre 263 ± 5a 1.1 ± 0.6a 132 ± 5a 0.7 ± 0.1a 2.2 ± 0.2a 37 ± 6a 66 ± 3a
(N = 8)
NX+V 286 ± 9a,b 1.4 ± 0.1b 158 ± 4a,b 0.6 ± 0.1a 2.0 ± 0.1a 48 ± 4a,b 78 ± 4a,b
(N = 8)
NX+L50 291 ± 6a,b 1.5 ± 0.1b 138 ± 4ac 0.7 ± 0.1a 2.5 ± 0.2a 34 ± 3a,c 64 ± 3a,c
(N = 8)
NX+L500 288 ± 6a,b 1.5 ± 0.1b 124 ± 3c,d 0.7 ± 0.1a 3.2 ± 0.3a,b,c 24 ± 2a,b,c,d 59 ± 1b,c
(N = 8)
NX+HH 292 ± 6a,b 1.6 ± 0.1b 112 ± 5b,c,d 0.6 ± 0.1a 2.5 ± 0.3a 33 ± 7a 70 ± 3a,c,e
(N = 8)
Abbreviations are: BW, body weight; LKW, left kidney weight; MAP, mean arterial pressure; GFR, glomerular filtration rate; RPF, renal plasma flow; RVR, renal
vascular resistance; PGC, glomerular hydraulic pressure. Results expressed as mean ± SE.
aP < 0.05 vs. S; bP < 0.05 vs. NXpre; cP < 0.05 vs. NX+V; dP < 0.05 vs. NX+L50; eP < 0.05 vs. NX+L500.
The extent of renal infiltration by macrophages and
Ang II-positive cells was evaluated in a blinded manner at
×250 magnification and expressed as cells/mm2. For each
section, 25 microscopic fields, each corresponding to an
area of 0.06 mm2, were examined. Since interstitial AT1R
in NX rats was often so densely expressed as to preclude
the individualization of positively stained cells, AT1R ex-
pression had to be estimated by a point-counting tech-
nique similar to the one employed to determine%INT.
This technique allowed us to assess the distribution of
AT1R among several compartments of the renal cortex
(glomeruli, vessels, tubules, and interstitium).
Statistical analysis
Differences among different groups were analyzed us-
ing one-way analysis of variance (ANOVA) with pair-
wise post-test comparisons by the Neuman-Keuls method
[28]. Since GSI and albumin excretion rates exhibited
a strong non-Gaussian distribution, log transformation
of these data was performed prior to statistical analysis.
For similar reasons, parameters expressed as proportions
underwent arcsine transformation before analysis [28].
Differences between TCP and UalbV measurements ob-
tained in the same rats at 30 and 120 days after ablation
were analyzed using the Student paired t test. P values
less than 0.05 were considered significant.
RESULTS
Functional studies
Functional parameters obtained at 30 days of treat-
ment (60 days after ablation), as well as those verified in
group NXpre (pretreatment reference values obtained at
30 days after ablation), are given in Table 1. Growth was
stunted in all groups subjected to renal ablation. How-
ever, there was no difference in body weight among the
NX groups, except for group NXpre, which was followed
during only 30 days. Kidney weight (KW) was also lower
in this group. In the remaining NX groups, KW was simi-
lar to that in group S, indicating the occurrence of marked
renal hypertrophy, since renal mass had been initially re-
duced by 5/6. MAP reached 132 ± 5 mm Hg 30 days after
ablation (group NXpre), a value significantly higher than
that in group S (114 ± 2 mm Hg, P < 0.05). L50 treat-
ment (group NX+L50) attenuated hypertension (138 ±
4 mm Hg, P < 0.05 vs. NX+V and S). Both L500 and
HH treatments brought MAP to values not statistically
different from those obtained in S or NXpre (124 ± 3 mm
Hg and 112 ± 5, respectively, P < 0.05 vs. NX+V, and
P > 0.05 vs. S, NXpre, and NX+L50). There were no
significant differences among the NX groups regarding
GFR, which in each of them was approximately half as
high as in S (P < 0.05). A similar pattern was observed for
RPF, except for group NX+L500, in which FPR was sig-
nificantly higher than in the remaining NX groups. RVR
increased by more than 250% in group NXpre (37 ± 6 mm
Hg/mL/min vs. 14 ± 1 in S, P < 0.05). Renal vasoconstric-
tion was aggravated 60 days after ablation (RVR rose to
48 ± 4 mm Hg/mL/min in group NX+V, P < 0.05 vs. S
and P > 0.05 vs. NXpre), and attenuated in groups L50
and HH (34 ± 3 and 33 ± 7 mm Hg/mL/min, respectively,
P < 0.05 vs. S, and P > 0.05 vs. NX+V). L500 treatment
brought RVR to levels significantly lower than in group
NX+V, and not statistically different from S or NXpre
(24 ± 2 mm Hg/mL/min, P < 0.05 vs. NX+V, P > 0.05 vs.
S and NXpre).
Long-term studies
Four out of 18 rats (22%) were lost in group NX+V.
Only 1 out of 17 and 1 out of 15 rats (6 and 7%, respec-
tively) died in groups NX+L50 and NX+HH, respec-
tively, whereas mortality was zero in group NX+L500. As
in the functional studies, renal ablation always promoted
growth stunting, whereas no significant differences were
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observed among the NX groups. Similar findings were
obtained regarding left kidney weight (LKW), except for
group NX+L500, in which LKW, unlike in the functional
studies, was significantly lower than in group NX+V (data
not shown). The behavior of TCP and UalbV at 30 and 120
days after ablation is represented in Figure 1A and B, re-
spectively. Initial (30-day) TCP values were uniformly el-
evated among all NX groups compared to S, and similar,
as expected, to those found in group NXpre (201 ± 9 mm
Hg, P < 0.05 vs. S). At 120 days after ablation, hyperten-
sion was aggravated in group NX+V (231 ± 4 mm Hg,
P < 0.05 vs. the respective 30-day value). L50 treatment
prevented further elevation of blood pressure, which nev-
ertheless remained at severely hypertensive levels (203 ±
8 mm Hg, P < 0.05 vs. S and NX+V). Treatment with L500
lowered TCP below pretreatment levels (177 ± 7 mm Hg,
P < 0.05 vs. S, NX+V, NX+L50, and pretreatment lev-
els). HH therapy was even more effective, bringing final
TCP to levels similar to those seen in S (157 ± 6 mm Hg,
P < 0.05 vs. NX+V, NX+L50, and pretreatment levels, P
> 0.05 vs. S). Initial (30-day) albuminuria was uniformly
increased among groups, and about 16-fold higher than in
S. Albuminuria was aggravated 120 days after ablation in
untreated NX rats (129 ± 13 mg/24h in group NX+V, P <
0.05 vs. S). Treatment with L50 promoted a numerical de-
crease in UalbV (100 ± 17 mg/24h in group NX+L50, P <
0.05 vs. S and P > 0.05 vs. NX+V). With L500 treatment,
albuminuria regressed relative to pretreatment values (46
± 7 mg/24h, P < 0.05 vs. S, pretreatment values, NX+V,
and NX+L50). HH promoted no amelioration of albu-
minuria (120 ± 13 mg/day, P < 0.05 vs. S, pretreatment
values, and NX+L500, P > 0.05 vs. NX+V).
The GSI in the several groups is represented in
Figure 2. In group NXpre (pretreatment reference), GSI
was 15 ± 5, significantly higher than in group S (0.13
± 0.09), showing that glomerular injury already existed
30 days after ablation. These lesions were exacerbated
120 days after ablation (139 ± 43 in group NX+V, P <
0.05 vs. groups S and NXpre). L50 treatment reduced GSI
numerically relative to NX+V, although this difference
was not statistically significant (68 ± 23, P < 0.05 vs. S and
NXpre, P > 0.05 vs. NX+V). By contrast, GSI remained
at levels not statistically different from pretreatment val-
ues in group NX+L500 (22 ± 6, P < 0.05 vs. S, NX+V,
and NX+L50, P > 0.05 vs. NXpre). HH treatment had a
similar effect on GSI as was obtained with the L50 reg-
imen (67 ± 13, P < 0.05 vs. S, NXpre, and NX+L500, P
> 0.05 vs. NX+V). A quantitative analysis of renal inter-
stitial expansion, expressed by the fraction of the cortical
area occupied by interstitial tissue (%INT), can be seen
in Figure 3. In group NXpre,%INT was 10-fold as high as
in group S (2.2 ± 0.5% vs. 0.2 ± 0.1 in S, P > 0.05). The
interstitial area was markedly expanded 120 days after
ablation, reaching 8.3 ± 1.2% in group NX+V (P < 0.05
vs. S and NXpre). L50 and HH treatments promoted slight
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Fig. 1. (A) Tail-cuff pressure, TCP, and (B) urinary albumin excretion
rate, UalbV, 30 and 120 days after renal ablation in groups S (sham),
NX+V (no treatment), NX+L50 (losartan, 50 mg/kg/day), NX+L500
(losartan, 500 mg/kg/day), and NX+HH (hidralazine, 24 mg/kg/day,
and hydrochlorothiazide, 6 mg/kg/day). Results expressed as mean ±
SE. ∗P < 0.05 vs. respective pretreatment; aP < 0.05 vs. S; bP < 0.05 vs.
NX+V; cP < 0.05 vs. NX+L50; dP < 0.05 vs NX+L500.
numerical, not statistically significant, decreases in%INT
relative to untreated NX (6.2 ± 0.8% and 5.8 ± 0.7%, re-
spectively, P < 0.05 vs. S and NXpre, P > 0.05 vs. NX+V).
High-dose L treatment L500 reduced%INT to 4.1 ± 0.6
in group NX+L500, a value significantly different from
that in group NX+V.
The extent of renal interstitial macrophage infiltration
is represented in Figure 4. In group NXpre, the interstitial
macrophage density more than tripled compared to that
in S (71 ± 10 vs. 17 ± 2 cells/mm2, P < 0.05). Macrophage
infiltration was exacerbated in group NX+V 120 days af-
ter ablation, reaching 133 ± 17 cells/mm2 (P < 0.05 vs.
S and NXpre). Neither L50 nor HH ameliorated the in-
tensity of macrophage infiltration (107 ± 20 and 121±14
cells/mm2 in groups NX+L50 and NX+HH, respectively,
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Fig. 2. Glomerulosclerosis index (GSI) 120 days after renal ablation
in groups S (sham), NXpre (30 days after renal ablation, used as
pretreatment reference), NX+V (no treatment), NX+L50 (losartan,
50 mg/kg/day), NX+L500 (losartan, 500 mg/kg/day), and NX+HH
(hidralazine, 24 mg/kg/day, and hydrochlorothiazide, 6 mg/kg/day). Re-
sults expressed as mean ± SE. aP < 0.05 vs. S; bP < 0.05 vs. NXpre; cP
< 0.05 vs. NX+V; dP < 0.05 vs. NX+L50; eP < 0.05 vs. NX+L500.
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Fig. 3. Fraction of cortical area occupied by interstitium (%INT)
in groups S (sham), NXpre (30 days after renal ablation, used as
pretreatment reference), NX+V (no treatment), NX+L50 (losartan,
50 mg/kg/day), NX+L500 (losartan, 500 mg/kg/day), and NX+HH
(hidralazine, 24 mg/kg/day, and hydrochlorothiazide, 6 mg/kg/day). Re-
sults expressed as mean ± SE. aP < 0.05 vs. S; bP < 0.05 vs. NXpre; cP
< 0.05 vs. NX+V.
P < 0.05 vs. S and NXpre, and P > 0.05 vs. NX+V). By
contrast, L500 treatment kept macrophage infiltration at
levels not statistically different from those observed in
group NXpre (68 ± 8 cells/mm2, P < 0.05 vs. S, NX+V,
and NX+HH). Figure 5 shows the immunohistochemi-
cal expression of Ang II in an afferent arteriole, such as
typically observed in sham-operated control subjects. A
quantitative analysis of this expression in Ang II-positive
profiles/mm2 is given in Figure 6, showing that, in the NX
groups, this value was invariably lower than in group S.
Figure 7 shows a typical inflamed renal interstitial area in-
filtrated by Ang II-positive cells, whereas Figure 8 shows
the extent of this infiltration among the several groups. In
group NXpre, the density of Ang II-positive cells was 5.2
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Fig. 4. Intensity of interstitial macrophage infiltration (in cells/mm2)
in groups S (sham), NXpre (30 days after renal ablation, used as
pretreatment reference), NX+V (no treatment), NX+L50 (losartan,
50 mg/kg/day), NX+L500 (losartan, 500 mg/kg/day), and NX+HH
(hidralazine, 24 mg/kg/day, and hydrochlorothiazide, 6 mg/kg/day). Re-
sults expressed as mean ± SE. aP < 0.05 vs. S; bP < 0.05 vs. NXpre; cP
< 0.05 vs. NX+V; dP < 0.05 vs. NX+L50; eP < 0.05 vs. NX+L500.
50 µm
Fig. 5. Microphotography showing cells staining positively for an-
giotensin II (darker areas), detected by imunohistochemistry in an af-
ferent arteriole (4-lm thick section, ×200).
± 0.9 cells/mm2, over 2-fold higher than in S (P < 0.05).
At 120 days, this value reached 11.2 ± 2.3 cells/mm2 in
group NX+V (P < 0.05 vs. S and NXpre). Neither L50
nor HH treatment had a significant effect on this param-
eter, while L500 therapy kept it at levels indistinguishable
from pretreatment values (5.1 ± 0.8 cells/mm2, P < 0.05
vs. NX+V, P > 0.05 vs. S and NXpre).
A typical pattern of the AT1R expression in the S group
is shown in Figure 9A, in which AT1R appears mostly
in tubules, whereas glomeruli, vessels, and the renal in-
terstitium show only weak AT1R expression. As shown
previously in this laboratory [17], renal mass reduction
changed dramatically the AT1R intrarenal distribution
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Fig. 6. Quantitative analysis of the Ang II content (in cells/mm2) of
afferent arterioles in groups S (sham), NXpre (30 days after renal abla-
tion, used as pretreatment reference), NX+V (no treatment), NX+L50
(losartan, 50 mg/kg/day), NX+L500 (losartan, 500 mg/kg/day), and
NX+HH (hidralazine, 24 mg/kg/day, and hydrochlorothiazide, 6
mg/kg/day). Results expressed as mean ± SE. aP < 0.05 vs. S.
25 µm
Fig. 7. Microphotography showing cells staining positively for an-
giotensin II (darker areas), detected by imunohistochemistry, in an in-
terstitial inflamed area in a rat from group NX+V (4-lm thick section,
×400).
pattern at 120 days (Fig. 9B), when most of the AT1R
expression was located in the interstitial compartment,
especially at inflamed areas. AT1R distribution was not
affected by L50 or HH treatments, whereas L500 restored
the pretreatment pattern (Fig. 9C). To better evaluate the
intrarenal AT1R distribution, the ratio between its inter-
stitial and tubular expressions was calculated in all groups
(Fig. 10). In S, this ratio was very small (0.09 ± 0.02), indi-
cating an almost complete predominance of the tubular
expression of AT1R. Interstitial shifting was already ev-
ident 30 days after ablation (0.5 ± 0.1 in group NXpre,
P < 0.05 vs. S), and reached a maximum 120 days after
ablation (9.1 ± 2.9 in group NX+V, P < 0.05 vs. S and
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Fig. 8. Quantitative analysis of the Ang II content (in cells/mm2)
in the cortical interstitium of groups S (sham), NXpre (30 days
after renal ablation, used as pretreatment reference), NX+V (no
treatment), NX+L50 (losartan, 50 mg/kg/day), NX+L500 (losartan,
500 mg/kg/day), and NX+HH (hidralazine, 24 mg/kg/day, and hy-
drochlorothiazide, 6 mg/kg/day). Results expressed as mean ± SE. aP
< 0.05 vs. S; bP < 0.05 vs. NXpre; cP < 0.05 vs. NX+V.
NXpre). Treatment with L50 or HH promoted a numeri-
cal, not statistically significant decrease in this parameter
(3.6 ± 0.8 and 4.9 ± 0.9, respectively, P < 0.05 vs. S and
NXpre, P > 0.05 vs. NX+V). L500 treatment reduced the
interstitial/tubular ratio to 1.3 ± 0.2 (P < 0.05 vs. all the
other groups).
Group NX+V exhibited a modest but significant hy-
perkalemia at day 120 compared to S (4.4 ± 0.2 mmol/L
vs. 3.4 ± 0.1 in S, P < 0.05). Treatment with either L50 or
L500 promoted no further elevation of plasma K+ levels
(4.4 ± 0.2 and 4.5 ± 0.1, respectively, P < 0.05 vs. S and P >
0.05 vs. NX). Not unexpectedly, plasma K+ concentration
was brought to normal levels by the HH treatment (3.5 ±
0.1, P > 0.05 vs. S and P < 0.05 vs. NX). No variation was
observed among groups regarding plasma sodium levels
(data not shown).
DISCUSSION
As expected, 5/6 renal mass removal led to progres-
sive hypertension, albuminuria, glomerulosclerosis, and
interstitial expansion, all of which may have been un-
derestimated given the 22% mortality in the untreated
group, since the animals that succumbed were likely those
with worst renal injury. As in previous studies [4, 29,
30], renal injury was clearly associated with severe and
progressive systemic and glomerular hypertension, which
likely played a major pathogenic role. However, abun-
dant experimental evidence [4, 15, 31, 32] now indicates
that the development of progressive renal injury requires
that hemodynamic stress be coupled with inflammatory
events, such as the severe and progressive macrophage
infiltration seen in NX rats. In vitro evidence suggests
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A B C
Fig. 9. Representative microphotographs showing the distribution of the AT1 receptor (darker areas) in the renal tissue of rats from groups S (A),
NX+V (B), and NX+L500 (C) (4-lm thick section, ×200).
that inflammation can actually be caused directly by me-
chanical stimulation [31–34].
As described previously in association with the NX
model [17] and the chronic NO inhibition model [19, 35],
Ang II could be detected by immunohistochemistry at
2 main intrarenal locations: at the final portion of the
afferent arterioles (AA), and the renal interstitium. In
normal S rats, Ang II-positive cells were easily seen at
AA, but appeared infrequently at the interstitial area.
This pattern was inverted 30 days after ablation, at which
time the arteriolar expression of Ang II had fallen pre-
cipitously, while a large number of Ang II-positive cells
had appeared in areas of interstitial inflammation. This
abnormality was exacerbated 120 days after ablation, in
parallel with the aggravation of renal structural injury.
These findings suggest that, at these 2 locations, Ang II
exerts quite different functions. At the AA, Ang II seems
to participate, as it would be expected, in the process of
renal sodium conservation, varying inversely with extra-
cellular volume, being thus depressed under conditions of
severe renal mass reduction. By contrast, the interstitial
expression of Ang II, rather than reflect the extracellular
volume status, appeared intimately associated with the
process of interstitial inflammation characteristic of this
model. The exact cell origin of this “anomalous” Ang
II is unclear, since both tubular and several types of in-
flammatory cells can produce Ang II, or at least possess
the necessary biochemical machinery [16, 19, 36, 37]. Ad-
ditionally, Ang II may have been produced by tubular
cells and undergone internalization after binding to the
AT1 receptor, which is known to be expressed by inter-
stitial inflammatory cells [38, 39]. It is worth noting that
mechanical stress, such as caused by glomerular hyper-
tension, can enhance the production of Ang II [40], and
the expression of the AT1 receptor [41].
Whatever its origin, Ang II is likely to have been in-
volved in the process of chronic inflammation and fibro-
sis that took place at the renal interstitium. Ang II is
known to participate in the activation of lymphocytes
and monocytes [13, 42], to stimulate the activation of the
nuclear-kappa B factor [11] and the expression of several
inflammatory mediators and growth factors [11, 43–46],
the proliferation of both inflammatory and parenchymal
cells [47, 48], the activation of intracellular inflammatory
pathways [49], and the synthesis of extracellular matrix
[50, 51].
The renal distribution pattern of the AT1 receptor was
already altered at 30 days of ablation, before treatments
were begun, with the interstitial/tubular ratio increasing
several fold relative to the value observed in S. This shift
of the AT1 receptor expression toward the interstitium
was dramatically increased at day 120, confirming recent
observations of this laboratory using the NX model [17].
The AT1 receptor was shown to be expressed by cells
involved in the inflammatory response, such as lympho-
cytes, macrophages, and myofibroblasts [13, 36, 48], and
may therefore have contributed decisively to the intense
interstitial inflammation observed in this study. The si-
multaneous presence of large amounts of Ang II and of
its main receptor at the limited space of the renal inter-
stitium is likely to have resulted in intense paracrine and
even autocrine stimulation of inflammatory cells, estab-
lishing a positive feedback that culminated in the severe
destruction of renal parenchyma observed at day 120.
Monotherapy with L at the “conventional” dose of 50
mg/kg/day promoted only modest reduction of hyperten-
sion and albuminuria relative to untreated NX rats Ac-
cordingly, the parameters of glomerular and interstitial
injury 120 days after renal ablation in group NX+L50
were only slightly lower than, and not statistically dif-
ferent from, those observed in untreated NX rats. These
results are consistent with previous observations of ex-
perimental models of chronic kidney disease and clinical
trials, which indicate that, when initiated late in the course
of chronic kidney disease, treatment with ACE inhibitors
or AT1 blockers can slow, but not detain, the progres-
sion toward advanced renal insufficiency [21–25]. The
reasons why only incomplete protection is afforded by
late treatment with suppressors of the renin-angiotensin
system are currently unclear. However, the present study
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Fig. 10. Quantitative analysis of the ratio between the interstitial and
tubular expressions of the AT1 receptor in groups S (sham), NXpre
(30 days after renal ablation, used as pretreatment reference), NX+V
(no treatment), NX+L50 (losartan, 50 mg/kg/day), NX+L500 (losar-
tan, 500 mg/kg/day), and NX+HH (hidralazine, 24 mg/kg/day, and hy-
drochlorothiazide, 6 mg/kg/day). Results expressed as mean ± SE. aP
< 0.05 vs. S; bP < 0.05 vs. NXpre; cP < 0.05 vs. NX+V; dP < 0.05 vs.
NX+L50; eP < 0.05 vs. NX+L500.
offers some possible explanations for this limitation.
Although L50 treatment did attenuate systemic hyper-
tension, blood pressure was never returned to normal,
remaining at the very high levels already observed be-
fore treatment. Since hypertension has been pointed out
by some investigators to be a major pathogenic factor in
the progression of chronic kidney disease [52], the persis-
tently heightened blood pressures in the L50 group might
help to explain the narrow difference between the renal
injury observed in these rats and in untreated NX rats.
However, it must be noted that blood pressure was nearly
normalized in the group that received HH treatment, in
which renal injury parameters were similar to those of un-
treated NX rats, suggesting that additional factors had a
more decisive pathogenic role. In consistency with previ-
ous observations [25, 53], treatment with L50 attenuated
glomerular hypertension in NX rats. However, glomeru-
lar pressure remained 11 mm Hg above the levels ob-
served in S, which might help to explain the continued
progression of glomerular injury in this group. On the
other hand, L50 treatment promoted no significant alter-
ation in the intensity of the renal interstitial macrophage
infiltration, the renal expression of Ang II-positive cells,
or the intrarenal distribution of the AT1 receptor in NX
rats. Thus, L50 monotherapy had only partial effect on
either the hemodynamic or the inflammatory events as-
sociated with the development of progressive nephropa-
thy in the NX model, which helps to explain its limited
protective action.
Treatment with L at a dose 10-fold higher than for
group L50, and 50-fold higher than those usually em-
ployed in experimental studies, arrested the progres-
sion of both glomerulosclerosis and interstitial expansion,
keeping the respective parameters at pretreatment lev-
els even at 120 days after renal ablation, whereas TCP
and UalbV regressed to values significantly lower than
those observed before treatment. In addition, mortality
was reduced to zero in this group, compared to 22% in
untreated NX rats and 6% in the L50 group. The de-
gree of protection obtained in these NX rats with L500
was higher than with late treatment with enalapril [54],
and similar to that achieved with an association of L50
with either mycophenolate mofetil [25] or a nonsteroidal
anti-inflammatory [17]. Thus, these results indicate that
the renoprotective effect of AT1 blockade is strongly
dose dependent, and that achievement of maximal ben-
eficial effects may require doses one order of magnitude
higher than those currently employed. This dose depen-
dence of losartan is likely to be observed in humans as
well, since clinical studies showed that the human re-
sponse can be predicted with reasonable accuracy from
animal experiments [55], although studies of the kinet-
ics of very high ARB doses in humans have not been
performed.
The superior protection conferred by the high-dose L
treatment might be ascribed to the much more intense
and long-lasting antihypertensive effect of this regimen
compared with that obtained in the L50 group. However,
blood pressure was lowered to the same extent by the
HH treatment, yet albuminuria and the parameters of
renal injury in this group were similar to those found
in rats treated with L50, in which hypertension was less
well controlled. Thus, the additional protection brought
by the high dose L treatment must have been indepen-
dent of blood pressure and related, in all likelihood, to
some intrarenal effect. Indeed, the L500 treatment re-
duced the RVR to levels half as high as in untreated NX
rats, and 30% lower than in groups NX+L50 or NX+HH.
This marked vasodilatation was likely associated with a
higher sodium excretion capability, which helps to explain
the more efficacious antihypertensive effect of the L500
treatment [56]. In addition, PGC was 5 mm Hg lower in
this group compared with L50. However, it is uncertain
whether this difference, which was not statistically signif-
icant, can account for the remarkable additional effects
of L500 on renal structure.
The additional protection afforded by L500, not sat-
isfactorily explained by its effect on either systemic or
glomerular hemodynamics, may be attributed, at least in
part, to an anti-inflammatory action. Treatment with L500
markedly limited the renal infiltration by macrophages,
which remained close to, or even below, the levels ob-
served before treatments were started. The amount of
interstitial cells staining positively for Ang II was equally
limited to pretreatment values. In addition, and unlike
L50 or HH treatments, L500 shifted the intrarenal distri-
bution of AT-1 receptor toward the pattern observed be-
fore treatments, limiting its expression at the interstitium
1922 Fujihara et al: High-dose losartan in the remnant model
and enhancing it at the tubules. Together, these obser-
vations are consistent with our working hypothesis that,
given the intense interstitial expression of the AT-1 recep-
tor, a much larger dose of L (or of any ARB) is necessary
to counteract the proinflammatory effects of Ang II. An
additional possibility is that the “anomalous” AT-1 recep-
tors possess higher affinity for Ang II than at the vessels,
thus requiring higher concentrations of L to be blocked,
although at present this possibility must remain entirely
speculative, given the absence of appropriate evidence.
It is conceivable that AT-1 binding triggers intracellular
inflammatory events, such as generation of reactive oxy-
gen species and activation of the NF-kappa-B and MAP
pathways [11, 49, 51, 57, 58], recruiting more inflamma-
tory cells, that will in turn produce Ang II and/or express
the AT-1 receptor, thus establishing a positive feedback,
and causing an exponential growth of the inflammatory
infiltrate. The administration of a high dose of L may have
interrupted this vicious cycle, thus limiting inflammation
and preserving the renal structure more effectively than
the “conventional” dose of L.
Despite its remarkable effect on interstitial Ang II,
treatment with L500 did not normalize the “physiologic”
expression of Ang II at the afferent arterioles. The reason
for this apparently unexpected finding is unclear. How-
ever, it must be noted that normalization of blood pres-
sure was not achieved with L500 treatment, indicating
that some degree of extracellular volume expansion per-
sisted in this group, and that additional measures may be
required to adequately enhance sodium excretion by the
remnant renal tissue.
It is important to note that L could be administered
at an extremely high dose without any perceptible toxic
effect. Rats receiving this treatment grew at the same
rate as untreated rats or rats receiving the lower L dose.
No hypotension was seen in the group L500, in either
awake or anesthetized rats, while GFR was identical to
that obtained in groups NX+V and NX+L50. Plasma
potassium concentration was not higher in group L500
than in the other NX groups, as it might be expected.
This finding suggests that, in the NX model, potassium
excretion is relatively independent of AT-1 stimulation
by Ang II. Circulating aldosterone concentration is actu-
ally increased in this model [59], even though the renin
levels are depressed [60]. Elevated potassium levels can
directly stimulate aldosterone synthesis by the adrenals
[61], and the insertion of potassium channels at the lumi-
nal membrane of principal cells at the collecting duct [62],
leading to enhanced potassium excretion and limiting hy-
perkalemia. Although the present observations cannot be
applied to clinical practice before careful toxicology tests
are carried, recent evidence suggests that ARB doses in
large excess of those currently recommended may be well
tolerated even by patients suffering from chronic kidney
disease [63].
CONCLUSION
Late treatment of NX rats with a very high dose of
losartan afforded more effective renal protection com-
pared to treatment with “conventional” doses, arresting
the parameters of renal injury and inflammation at the
levels observed prior to treatment. The superiority of this
regimen cannot be satisfactorily explained by its action on
systemic or intrarenal hemodynamics, and may be largely
due to an anti-inflammatory effect. The present findings
indicate that the renal protection conferred by ARB is
dose dependent, and that the doses necessary for maximal
protection may be several fold higher than those currently
adopted. Although hyperkalemia and other toxic effects
were not observed in the present study, careful tests are
necessary to establish whether high doses of ARB can be
equally safe and effective in the clinical management of
chronic nephropathies.
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